Morinaga Milk's B. longum BB536 Probiotic May Prevent Intestinal Disorders Induced by Animal-Based Diet
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading dairy product company in Japan, today unveiled new research showing that daily consumption of yogurt fortified with the company’s proprietary probiotic Bifidobacterium longum BB536 prevents the intestinal bacterial imbalance induced by an animal-based diet. BB536 maintained healthy levels of beneficial bacteria, while preventing increases of harmful levels of bacteria such as Bilophila.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160211005072/en/
Recently, studies have demonstrated the importance of maintaining balanced intestinal flora to overall health. However, the modern, fast-paced lifestyle — with its lack of sleep and exercise, irregular dietary habits and continual stress — threatens bacterial balance. Eating an animal-based diet in particular has been shown to cause an increase in harmful bacteria, a condition known as dysbiosis. This problem is not confined to the United States. Due to Westernization, animal-based diets are growing in popularity in countries across the world.
The effect of animal products on bacterial balance is strong and immediate. In fact, a 2014 study published in the scientific journal Nature showed that consumption of an animal-based diet composed entirely of meat and eggs for just one day caused negative changes in the composition and function of intestinal flora, including dysbiosis.1 However, consumption of BB536-fortified yogurt prevented these harmful changes, as shown in Morinaga’s new research.
“Consumption of BB536-fortified yogurt prevented the GI deterioration caused by an animal-based diet, which indicates it may be able to prevent various intestinal disorders caused by eating a poor diet — just by adding one BB536 yogurt to the daily diet per day,” Dr. Jin-zhong Xiao, General Manager of Morinaga’s Next Generation Science Institute, explained.
“Importantly, probiotics are not interchangeable.” Dr. Xiao points out that “Probiotics are all strain-specific, as each strain has different indications and characteristics. Bifidobacterium longum is one of the predominant bacteria in the human intestine, and it is clinically confirmed that yogurt containing BB536 is more efficacious for eliminating harmful substances and modulating intestinal microflora compared to conventional yogurt.”
In the study, 31 healthy adults were randomly classified into 3 groups (A, B and C). After an observation period of 7 days, the subjects consumed an animal-based diet consisting entirely of meat and eggs for 5 days (the animal-based diet period) followed by a balanced diet (the recovery period) for 14 days. Group A consumed no BB536 yogurt during the whole study period, while group B consumed 100g of BB536 yogurt twice a day during the recovery period only, and group C consumed 100g of BB536 yogurt twice a day during both the animal-based diet period and the recovery period. Throughout the study, fecal samples were collected, and intestinal bacterial flora was analyzed before and after the animal-based diet period and after the recovery period (Fig. 1).
BB536 Yogurt Prevents Decrease in Beneficial Bifidobacteria (Fig.2 Left)
Bifidobacteria counts in the feces decreased significantly during the animal-based diet period in both groups A and B. However, this decrease was not observed in subjects in group C, who consumed BB536 yogurt together with the animal-based diet. Moreover, the Bifidobacteria tended to decrease further during the recovery period in group A, which ate no BB536 yogurt, while it tended to increase in group B, getting close to the original condition before starting the animal-based diet. These findings demonstrate the potential of Bifidobacterium longum BB536 not only to prevent diet-related gut flora disorders, but also to aid in their recovery.
BB536 Yogurt Also Prevents Increase in Harmful Bilophila (Fig.2 Right)
Consistent with the results of the above-mentioned Nature study, the present study found that an animal-based diet increased a genus of harmful bacteria called Bilophila. Bilophila is thought to induce inflammation in the intestines by producing the harmful substance hydrogen sulfide, which damages the intestinal mucous membrane2 and has been reported to be elevated in patients with appendicitis.3 However, no significant increase of this harmful bacterial genus was observed in group C subjects. B. longum BB536 showed superior results in regulating intestinal function, had a protective effect against the enteropathogenic Escherichia coli O-1574 and helped eradicate the enterotoxigenic Bacteroides fragilis (ETBF), which is associated with the development of colorectal cancer.5
About Bifidobacterium longum BB536
BB536 is one of the strains of Human Residential Bifidobacteria, which naturally reside in human intestines and are natural parts of human digestive systems. It is one of the most thoroughly researched probiotic strains in the world. Morinaga has conducted research and development on BB536 for over 40 years and achieved GRAS status in the U.S. in 2009. Supported by over 120 published studies, BB536’s beneficial effects have been confirmed in such clinical areas as intestinal health, immunity, infection, and allergy.
Morinaga Milk Industry Co., Ltd. is one of the major dairy product companies in Japan. Founded in 1917 and employing over 3,000 people, Morinaga excels in innovative technology and offers dairy products and other beneficial functional ingredients to customers around the world. For more information, visit us at http://www.morinagamilk.co.jp/english/.
1. Nature 505, 559-563(2014)
2. Nature 487, 104-108(2012)
3. PLoS One 4, e95414(2014)
4. Bios. Microflora 22, 85-91(2003)
5. Anaerobe 18, 14-18(2012)
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers17.2.2018 21:00 | Pressemelding
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 08:00 | Pressemelding
Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 18:26 | Pressemelding
Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 17:05 | Pressemelding
General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges
Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 09:03 | Pressemelding
Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o
Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 08:00 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and